Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia

Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia

Waldenström macroglobulinemia (WM) is a distinct type of indolent lymphoplasmacytic lymphoma (LPL) with a high frequency of MYD88L265P mutation. Treatment for WM/LPL is highly variable in clinic and ibrutinib (a Bruton tyrosine kinase inhibitor, BTKi) has become a new treatment option for WM. To inv...

Full description

Bibliographic Details
Main Authors: Yingjun Wang, Vasantha Lakshmi Gali, Zijun Y. Xu-Monette, Dahlia Sano, Sheeba K. Thomas, Donna M. Weber, Feng Zhu, Xiaosheng Fang, Manman Deng, Mingzhi Zhang, Fredrick B. Hagemeister, Yong Li, Robert Z. Orlowski, Hans Chulhee Lee, Ken H. Young
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Waldenström macroglobulinemia
MYD88
CXCR4
TP53
Cytogenetic karyotype
Ibrutinib
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558621000087

Internet

http://www.sciencedirect.com/science/article/pii/S1476558621000087

Similar Items